Avantor Performance Materials has signed a collaboration agreement with Rubicon Research Private LTD of Mumbai, aimed at combining the Indian company’s proprietary product technology with Avantor’s expertise in manufacturing and marketing to develop next-generation products for the functional excipient market.
The immediate goal of the partnership is to develop and market a novel gastro-retentive excipient which can enable the delivery of molecules having a window of absorption. Introduction of this novel excipient will enable the industry to develop more options in a niche segment where the benefit of targeted delivery will result in significant therapeutic advantage.
The agreement calls for the companies to collaborate on key elements of the process of bringing new products to the pharmaceutical excipient market, including optimized commercial manufacturing and production, full regulatory registrations and approvals from the U.S. Food and Drug Administration to move toward full commercialization and potential licensing of the excipient materials.
The two companies said they would work to launch initial products resulting from the partnership in 2013.
Date: Oct. 16, 2012
Source: Avantor Performance Materials
Filed Under: Drug Discovery
